India's Cadila to end late-stage trials of potential COVID-19 vaccine in March
By Sumit Khanna
AHMEDABAD, India July 17 (Reuters) - India's Zydus Cadila CADI.NS plans to complete late-stage trials for its potential coronavirus vaccine in March 2021 and could produce up to 100 million doses a year if trials are successful, Chairman Pankaj Patel told Reuters.
Cadila's vaccine candidate, dubbed ZyCov-D, is one of dozens being developed around the world to fight the coronavirus.
(Writing by Zeba Siddiqui; Editing by Edmund Blair)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.